Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial - 18/08/11
, Ajay J. Kirtane, MD, SM b, Sabina A. Murphy, MPH a, Steve Rohrbeck, MD c, Venu Menon, MD d, Jeffrey Lins, MD e, Samer Kazziha, MD f, Ivan Rokos, MD g, Nicolas W. Shammas, MS, MD h, Theresa M. Palabrica, MD i, Polly Fish, BS a, Carolyn H. McCabe, BS a, Eugene Braunwald, MD afor the TIMI Study Group
Résumé |
Background |
Early restoration of epicardial flow before primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) has been associated with improved clinical outcomes.
Methods |
We hypothesized that early administration of the glycoprotein IIb/IIIa inhibitor eptifibatide in the emergency department (ED) would yield superior epicardial flow and myocardial perfusion before primary PCI compared with initiating eptifibatide after diagnostic angiography in the cardiac catheterization laboratory (CCL). Three hundred forty-three patients with STEMI were randomized to either early ED eptifibatide (n = 180) or CCL eptifibatide (n = 163).
Results |
The primary end point (pre-PCI corrected TIMI frame count) was significantly lower (faster flow) with early eptifibatide (77.5 ± 32.2 vs 84.3 ± 30.7, P = .049). The incidence of normal pre-PCI TIMI myocardial perfusion was increased among patients treated in the ED versus CCL (24% vs 14%, P = .026). There was no excess of TIMI major or minor bleeding among patients treated in the ED versus CCL (6.9% [12/174] vs 7.8% [11/142], P = NS).
Conclusion |
A strategy of early initiation of eptifibatide in the ED before primary PCI for STEMI yields superior pre-PCI TIMI frame counts, reflecting epicardial flow, and superior TIMI myocardial perfusion compared with a strategy of initiating eptifibatide in the CCL without an increase in bleeding risk.
Le texte complet de cet article est disponible en PDF.Plan
| Supported in part by a grant from the Millennium Pharmaceuticals, Cambridge, Mass, and Schering-Plough Research Institute, Kennilworth, NJ. |
Vol 152 - N° 4
P. 668-675 - octobre 2006 Retour au numéro
Article précédent
- Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks
- Ivan C. Rokos, David M. Larson, Timothy D. Henry, William J. Koenig, Marc Eckstein, William J. French, Christopher B. Granger, Matthew T. Roe
- Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes
- Raymond T. Yan, Andrew T. Yan, Mary Tan, Darren K. McGuire, Lawrence Leiter, David H. Fitchett, Claude Lauzon, Kevin Lai, Chi-Ming Chow, Anatoly Langer, Shaun G. Goodman, for the Canadian Acute Coronary Syndrome Registry Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?